DepleTTR-CM A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

15076ALXN2220-ATTRCM-301/NCT0618393OpenDepleTTR-CM A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NCT06183931IndustrialAdultTreatmentTransthyretin amyloid cardiomyopathy (ATTR)Sheikh, FarooqMedstar Washington Hospital Center : Hellina BirruMCRN - Heart Failure7317Hellina BirruHellina Birruhellina.t.birru@medstar.netClinical Research Coordinator 2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>